Key Facts Surrounding This News Item
- BOLD had a POWR Rating of D (Sell) coming into today.
- BOLD was -16.28% below its 10-Day Moving Average coming into today.
- BOLD was -19.73% below its 20-Day Moving Average coming into today.
- BOLD was -17.55% below its 50-Day Moving Average coming into today.
- BOLD was -20.49% below its 100-Day Moving Average coming into today.
- BOLD was -17.02% below its 200-Day Moving Average coming into today.
- BOLD had returned -4.56% year-to-date leading up to today’s news, versus a +5.65% return from the benchmark S&P 500 during the same period.
More Info About Audentes Therapeutics, Inc. (BOLD)
Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company was founded in 2012 and is based in San Francisco, California. View our full BOLD ticker page with ratings, news, and more.
Try StockNews.com Premium Today!
Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!